-
2023-505385-28-00
4
2023-10-19
male or pre/post-menopausal women age ≥ 18 years with locally advanced
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2023-503698-40-00
5
2023-03-23
Preeclampsia
-
2022-500069-29-00
9
2022-11-02
Alzheimer's disease
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2023-510346-25-00
5
2022-09-01
Hypereosinophilic Syndrome (HES)
-
2023-507029-40-00
5
2022-05-09
Genetic carriers of dilated cardiomyopathy causing variants
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-508956-20-00
5
2020-03-12
Hidradenitis suppurativa
-
2023-507149-27-00
5
2019-11-04
Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-521918-26-00
4
2026-02-11
HIV Infections
-
2024-520155-24-00
4
2025-10-16
Metastatic castration resistant prostate cancer (mCRPC)
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2025-520488-42-00
4
2025-09-17
Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
-
2024-520039-33-00
10
2025-08-11
Hidradenitis Suppurativa
-
2024-517143-31-00
4
2025-07-18
Autosomal Dominant Polycystic Kidney Disease
-
2024-513266-19-00
5
2025-06-13
Hidradenitis Suppurativa (HS)
-
2024-513511-27-00
4
2025-05-29
HR-negative/HER2-negative resectable stage I TNBC.
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2023-507306-13-00
4
2025-04-13
HER2-positive unresectable locally recurrent or metastatic breast canc